Hadasit Portfolio Companies to Receive Over $2.8M in Government Grants

Hadasit Bio-Holdings Ltd. and its portfolio companies ProtAb Ltd. and KAHR Medical Ltd. announced that they will receive additional funding of NIS 10.7 million (over $2.8 million) by the Israeli Ministry of Industry and Commerce, Office of the Chief Scientist (OCS) to support product development and advance clinical trials. ProtAb received approval for two programs totaling NIS 5.75 million (over $1.5 million) and KAHR received approval for two programs totaling NIS 4.95 million (over $1.3 million).